President Donald Trump plans to start with a “small tariff” on pharmaceutical imports before ramping duties up to 250% within ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA ...

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

The regulatory environment is placing extreme pricing pressure on pharmaceutical manufacturers. Their success in the market ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

BMN 390 fell short of an immunogenicity threshold that BioMarin was looking for to support its further development. Employees ...

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...